Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Τρίτη 18 Ιαν 2022
Due to fast spreading of SARS-CoV-2 a panel of experts of EBMT recommends the following guidelines for transplant units, recipients, and donors of hematopoietic cells. These guidelines will be updated when new information is obtained about COVID-19 epidemiology and clinical outcome.
Καταχωρήθηκε: Παρασκευή 07 Ιαν 2022
Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible for intensive therapies are offered an autologous hematopoietic cell transplant (HCT) as front-line consolidation followed...
Καταχωρήθηκε: Τετάρτη 29 Δεκ 2021
In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion,...
Καταχωρήθηκε: Πέμπτη 23 Δεκ 2021
In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in...
Καταχωρήθηκε: Τρίτη 14 Δεκ 2021
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. In this international, phase 3 trial, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy...
Καταχωρήθηκε: Δευτέρα 06 Δεκ 2021
Oμιλητής: Καθ. Αλέξανδρος Σπυριδωνίδης, 21ο Πανελλήνιο Συνέδριο Μεταμοσχεύσεων
Καταχωρήθηκε: Τετάρτη 01 Δεκ 2021
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with...
Καταχωρήθηκε: Τρίτη 23 Νοέ 2021
Η Novartis Oncology συνεχίζοντας τη δέσμευσή της να συμβάλλει στην ιατρική εκπαίδευση και στην επιστημονική ενημέρωση των επαγγελματιών υγείας, θα θέλαμε να σας ενημερώσουμε ότι το Τμήμα Αιματολογίας της Novartis συνεχίζει θα παρέχει για τρίτη συνεχόμενη χρονιά στους επαγγελματίες υγείας τη δυνατότητα να παρακολουθήσουν μέσω διαδικτύου την εικονική συνάντηση Ειδικών με θέμα...
Καταχωρήθηκε: Δευτέρα 15 Νοέ 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas
Καταχωρήθηκε: Τετάρτη 03 Νοέ 2021
Transplantation in lower-risk myelodysplastic syndromes Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas ​
Καταχωρήθηκε: Τετάρτη 27 Οκτ 2021
An analysis integrating ELN 2017, NPM1 MRD and KB scores to answer the question whether to transplant or not.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas
Καταχωρήθηκε: Πέμπτη 21 Οκτ 2021
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. Ιt was found that T cells of patients relapsing with AML after allo-HCT exhibited reduced glycolysis and interferon-γ production. Functional studies in multiple mouse models of leukemia showed that leukemia-derived lactic...
Καταχωρήθηκε: Τρίτη 12 Οκτ 2021
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds...
Καταχωρήθηκε: Παρασκευή 08 Οκτ 2021
Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas
Καταχωρήθηκε: Παρασκευή 08 Οκτ 2021
A study using lithium for epithelial regeneration in acute GvHD was presented. Presenter:Dr Liga  Participants:Prof.Spyridonidis, Dr Tsokanas
Καταχωρήθηκε: Τρίτη 21 Σεπ 2021
Rates of CLABSI are the same in internal jugular vein-and subclavian vein-CVC after allogeneic HCTThe strongest risk factor for local inflammation or fever are >6 neutropenic CVC-days·Time to local inflammation is longer with CVC placed in the internal jugular vein·CVC placed in the subclavian...
Καταχωρήθηκε: Τρίτη 14 Σεπ 2021
Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO). Efficacy and safety of nivolumab in real-life for the treatment of R/R Hodgkin lymphoma is comparable with that reported in clinical trials.·The main reasons for nivolumab discontinuation were referral for transplantation and disease...
Καταχωρήθηκε: Παρασκευή 10 Σεπ 2021
In a cohort of 126 allogeneic HCT recipients transplanted 1-39 years ago,62% were seropositive/seroprotected for measles before any vaccination since transplantation. The seropositivity/seroprotection was associated with myeloproliferative disorder, reduced intensity or non-myeloablative conditioning and absence of acute grade>2 graft-versus-host disease.·Our findings strongly support a systematic assessment...
Καταχωρήθηκε: Τετάρτη 08 Σεπ 2021
Presenter: Dr Liga, Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τρίτη 31 Αύγ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Βρέθηκαν 320 αποτελέσματα. Σελίδα 1 από 16
Σελίδα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2022 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας